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Imagining the future of cell therapies: clinical trials, innovation and 
the intersection of clinical-academic and commercial visions 
This paper examines the role of clinical trials in regenerative medicine 
innovation, exploring how trials have contributed to translational challenges in 
the field. Using data from an ethnographic study of UK cell therapy trials I 
interrogate the institutional framework for clinical trials and the identity-making 
of trialists. This analysis uncovers a disconnect between a commercially-aligned 
regulatory framework and a clinical-academic identity apparent in the majority of 
current trialling activity. These different pathways appear to represent two 
distinct sociotechnical imaginaries for cell therapies; one which reflects the 
assumptions of commercial innovation and prioritises economic success, and 
another which embodies the cultural expectations of academia and emphasises 
the importance of clinical care. These two imaginaries operate in synergy to some 
extent but there are significant tensions between them. How and to what extent 
these tensions are reconciled is likely to determine both the long-term success 
and the future shape of the field. 
Keywords: clinical trials, cell therapies, regenerative medicine, co-production, 
sociotechnical imaginaries 
  
1. Introduction 
Regenerative medicine, like tissue engineering before it, has witnessed 
increasingly high expectations that remain (as yet) largely unfulfilled. The past two and 
a half decades have seen significant progress in basic scientific research, such as the full 
mapping of the human genome, the isolation of human embryonic stem cells and the 
discovery of the CRISPR process for gene editing. However, these discoveries have not 
so far been successfully translated into effective, widely used clinical treatments. The 
halting progress of clinical regenerative medicine is exemplified by the fact only eight 
advanced therapy medicinal products (ATMPs) have been licensed in Europe to date. 
Four of these have since been suspended or withdrawn, leaving only four ATMPs 
currently authorised for use in Europe - all of which are treatments for rare and/or 
difficult to treat diseases and thus not in widespread use. In 2013 the House of Lords 
Science and Technology Committee conducted a review of regenerative medicine in the 
8.ZKLFKFRQFOXGHGWKDW³WKH8.LVFXUUHQWO\XQGHUSUHSDUHGWRUHDOLVHWKHIXOOSRWHQWLDO
RIUHJHQHUDWLYHPHGLFLQH´+R/)LYH\HDUVODWHUD+RXVHRI&RPPRQV6HOHFW
Committee report found that although progress has been made towards a comprehensive 
VWUDWHJ\IRUGHOLYHULQJUHJHQHUDWLYHPHGLFLQHWKHUHLVVWLOO³PXFKZRUNWREHGRQH´
(HoC 2017). Thus although regenerative medicine is generally thought to have great 
potential, there is a growing recognition that significant obstacles need to be overcome 
if this potential is to be realised.  
One of the main challenges identified in the House of Commons and House of Lords 
reports was the design and conduct of clinical trials, an issue that has also been 
highlighted in the academic literature (for instance Gardner et al. 2015; Webster 2013). 
Clinical trials form a bridge between the lab and the clinic (Webster 2013, 81), and are 
thus a key element of so-called translational medicine and an important locus of inquiry 
for understanding the dynamics of biomedical innovation. Although there are a number 
of comprehensive quantitative overviews of clinical trials activity in regenerative 
medicine (see for instance Li, Atkins, and Bubela 2014; Foley and Whitaker 2012)., 
there has to date been no comprehensive interrogation of the role that the clinical trials 
process plays in innovation in the field. In-depth case studies of specific trials have been 
conducted, for instance Hauskeller et al. (2017) explore the role of harmonization and 
standards in the multi-national BAMI trial, and Will (2011) discusses the challenges and 
tensions involved in undertaking a stem cell trial in the NHS. Although not focussed 
specifically on the role of trials in innovation, these studies of individual trials suggest 
that specific challenges experienced by clinical-academic trials could have an impact on 
the wider development of the field. This paper builds on this work examining the role of 
clinical trials in the development of one specific branch of regenerative medicine - cell 
therapies - LQWKHSDUWLFXODUFRQWH[WRIWKH8.'UDZLQJRQ-DVDQRII¶VLGLRPRIFR-
production, and the related concept of socio-technical imaginaries, I explore the role of 
clinical trials in innovation and investigate how this contributes to translational 
challenges in the field.  
The idiom of co-production argues that scientific knowledge cannot be separated from 
the context in which it is generated and focuses attention on the role that social 
institutions play in ordering and reordering our understanding of nature (Jasanoff 2004). 
Unlike some branches of Science and Technology Studies (STS), which focus primarily 
on the emergence of science and technology from the day-to-day practice of science, 
co-production encourages an examination of the political and societal aspects of 
knowledge governance. It does not take an entirely constructivist or socially-
deterministic position, focussing instead on the ways that science and society are 
mutually-configuring. Jasanoff distinguishes between constitutive co-production, which 
focuses on the construction of science and technology, and interactional co-production, 
which looks more closely at the tensions that emerge as new technologies and 
knowledge challenge existing practices and regulatory frameworks. This paper draws 
predominantly on the second of these, which directs attention to the epistemic and 
socio-political aspects of techno-science and argues that these do not develop separately 
from or as a result of science and scientific progress, but rather both emerge 
concurrently in an intertwined, recursive process. This concept is reflected in STS 
UHVHDUFKRQFOLQLFDOWULDOVVXFKDV.HDWLQJDQG&DPEURVLR¶VGHSLFWLRQRIFDQFHUWULDOV
HPHUJLQJDVDQHZµVW\OHRISUDFWLFH¶.HDWLQJDQG&DPEURVio 2007, 2012), and also in 
PXFKRIWKH676OLWHUDWXUHRQUHJHQHUDWLYHPHGLFLQHVXFKDV)DXONQHU¶VFRQFHSWRI
µJRYHUQDWLRQ¶)DXONQHUZKLFKGHVFULEHVWKHLPSDFWRIGLIIHUHQWLDODQGFKDQJLQJ
regulatory definitions on the development and deployment of Autologous Chondrocyte 
Implantation. Co-production provides a useful analytical toolkit for the STS researcher, 
most importantly the four common pathways - RUµRUGHULQJLQVWUXPHQWV¶- of co-
production that Jasanoff identifies: making identities, making institutions, making 
discourses and making representations. These ordering instruments are reflected in 
much of the STS literature on regenerative medicine: for instance, the concurrent 
emergence of science and the institutions that shape it has been highlighted in research 
on the UK Stem Cell Bank (Stephens, Atkinson, and Glasner 2011, 2008a, 2008b) and 
the Cell and Gene Therapy Catapult (Gardner and Webster 2017); different identities - 
and the tensions between them - are explored in studies of the translational medicine 
agenda (such as Wainwright et al. 2006; Brosnan and Michael 2014); the making of 
scientific representations, the ways that these representations travel and the work that 
they do are explored in studies of the development of standards, norms and shared 
understandings of cell therapies (Webster, Haddad, and Waldby 2011; Webster and 
Eriksson 2008; Eriksson and Webster 2015); and discourses are visible in research 
highlighting how expectations and promissory narratives about the future potential of 
cell therapies are deployed to create certain realities in the present (Martin, Brown, and 
Kraft 2008; Kitzinger and Williams 2005; Brown and Michael 2003).  
-DVDQRII¶VUHFHQWZRUNKDVIXUWKHUHODERUDWHGWKHLGLRPRIFR-production through the 
concept of socio-WHFKQLFDOLPDJLQDULHVZKLFKDUH³FROOHFWLYHO\KHOGLQVWLWXWLRQDOO\
stabilized, and publicly performed visions of desirable futures, animated by shared 
understandings of forms of social life and social order attainable through, and 
supportive of, DGYDQFHVLQVFLHQFHDQGWHFKQRORJ\´-DVDQRII-DVDQRIIDUJXHV
WKDWWKHVHLPDJLQDULHVDUH³ERWKSURGXFWVRIDQGLQVWUXPHQWVRIWKHFR-production of 
VFLHQFHWHFKQRORJ\DQGVRFLHW\´DQGWKDW³PXOWLSOHLPDJLQDULHVFDQFRH[LVWZLWKLQ
a society LQWHQVLRQRULQDSURGXFWLYHGLDOHFWLFDOUHODWLRQVKLS´,GHQWLI\LQJWKH
imaginaries that are shaping an emerging field, and examining the relationship between 
them, can thus help to explain not only how these intertwined phenomena mutually 
configure each other, but also why they do so in certain ways, in certain places or at 
certain times, and not in others - and thus why some potential outcomes materialise in 
any given context and others do not. Recent research has highlighted the important role 
that these imagined futures play in the co-production of science and society. In 
particular, studies have emphasised the role of institutions in elevating some 
imaginaries above others, allowing these versions to achieve dominance (Jasanoff 2015, 
4), and have also described how the making of identities is intertwined with visions of 
desirable outcomes for science and technological innovation (Burri 2015, 234).  
This paper examines the role of two ordering instruments of co-production in cell 
therapy trials, uncovering two distinctive socio-technical imaginaries that appear to be 
emerging in regenerative medicine: a commercial model that is implicit in cell therapy 
policy and regulation and enacted by the emerging institutional framework for trials, 
and a clinical-academic model that is articulated in the identities of trialists themselves. 
I describe the synergies and tensions between these two imaginaries and explore how 
the dynamic between them has created both opportunities and challenges for innovation, 
and in the concluding section I consider what this means for the role that clinical trials 
play in cell therapy innovation, and how the interactions between these two imaginaries 
in trials is shaping the co-production of science and social order for cell therapies.  
2. Methods 
The empirical data in this paper is drawn from a mixed methods study of UK 
cell therapy trials which involved four strands of data collection:  
1) Quantitative analysis of a data-set of UK cell therapy trials developed using 
information from online trial registries, published protocols, the 1,+5
SRUWIROLRGDWDEDVHLQGXVWU\SXEOLFDWLRQVPHGLDUHSRUWVDQGZRUGRIPRXWK 
2) 17 semi-structured interviews with individuals involved in cell therapy trials. 
Individuals working on ongoing trials in the UK data-set or on pre-clinical 
work for trials were identified from the online trial registries entries, word of 
mouth and the Cell and Gene Therapy Catapult¶VSUH-clinical database. All 
identified individuals were contacted and asked to participate, and all those 
who agreed were interviewed ± these included clinicians (8), scientific 
researchers/cell manufacturers (4) commercial cell therapy 
developers/consultants (3) and trials professionals (2). Five (30%) of the 
interviewees had some involvement in commercial studies, which is broadly 
in line with the proportion of UK cell therapy trials that are commercial. 
3) An ethnographic case study of one specific trial, including observation, 
documentary analysis and interviews. 7KHFDVHVWXG\VLWHFRQVLVWHGRID
FOLQLFDOWHDPLQYROYHGLQVXUJHU\DQGIROORZXSFDUHDFHOOPDQXIDFWXULQJ
IDFLOLW\DQGDOLQNHGVFLHQWLILFUHVHDUFKXQLW$OWKRXJKIRUWKHSXUSRVHVRI
DQRQ\PLW\,ZLOOQRWGHWDLOWKHVSHFLILFVRIWKHWUHDWPHQWRUFOLQLFDODUHD
WKHVHZHUHERWKUHODWLYHO\W\SLFDOIRUWKHILHOG7KHVLWHLVKRZHYHURQHRI
WKHPRUHHVWDEOLVKHGLQWHUPVRIWKHQXPEHUDQGVFDOHRIWULDOVLWKDVEHHQ
LQYROYHGLQZKLFKPD\OLPLWWKHDSSOLFDELOLW\RIWKHILQGLQJV 
4) Analysis of secondary sources (such as policy documents and trial protocols. 
and observation at events in the field (such as conferences, training courses 
and project meetings).  
 
Quantitative data were analysed using descriptive statistics and qualitative data were 
analysed using qualitative thematic content analysis, with the ordering instruments of 
co-production (identities, institutions, discourses and representations) were used as 
sensitising concepts. This analysis suggested that two different socio-technical 
imaginaries were emerging through different ordering instruments: a commercial model 
emerging through the institutional framework of cell therapies and a clinical-academic 
model emerging through an identity being constructed by the clinical-academic trialists 
themselves.  
To protect the anonymity of research participants the case study trial is referred to by 
the fictitious name ENABLE and all interviewees are anonymised. Given the number of 
cell therapy trials in the UK is so small I do not report certain information, such as 
specific clinical areas or type of cell being trialled, in any context where this could 
jeopardise anonymity. 
3. The institutions of cell therapy trials 
3.1 UK policy and regulatory environment 
Regenerative medicine policy in the UK (along with many other countries) tends to 
emphasise both its clinical and its economic potential, as reflected in this relatively 
W\SLFDOTXRWHIURPWKH+RXVHRI/RUGVUHSRUW³5HJHQHUDWLYHPHGLFLQHKDVWKHSRWHQWLDO 
to save lives and to help support the UK economy´+R/P\HPSKDVLV7KHFDVH
for investing in cell therapy innovation is thus established on the basis that this will help 
to achieve the dual policy objectives of improving health and creating wealth. In 
practice, however, the policy environment in the UK appears to be particularly aligned 
with wealth objectives - i.e. it predominantly assumes and/or facilitates the commercial 
aspects of innovation. For instance, one of the most influential actors in the field is the 
Cell and Gene Therapy Catapult (CGTC), which was established in 2012 (as the Cell 
7KHUDS\&DWDSXOWZLWKWKHDLPRIKHOSLQJWKH8.³EHDJOREDOOHDGHULQWKH
development, delivery and commercialisation RIFHOOWKHUDS\´&*7&P\
emphasis). The Catapult supports cell therapy innovation by providing developers with 
clinical, technical, regulatory and business expertise, and has also just opened a 
FHQWUDOLVHGFHOOPDQXIDFWXULQJFHQWUHZKLFK³ZLOOEHXVHGE\companies for the 
manufacture of late phase clinical trials and initial commercial supply of advanced 
WKHUDSHXWLFPHGLFLQDOSURGXFWVLQFOXGLQJFHOODQGJHQHWKHUDSLHV´&*7&P\
emphasis).  
Another example of a policy initiative which appears to particularly align with a 
commercial innovation model is adaptive licensing (AL), which is being explored as a 
means of ensuring patients have access to innovative new treatments as soon as 
possible. AL is ³a prospectively planned process, starting with the early authorisation of 
a medicine in a restricted patient population, followed by iterative phases of evidence 
gathering and adaptations of the marketing authorisation to expand access to the 
PHGLFLQHWREURDGHUSDWLHQWSRSXODWLRQV´(EMA, 2014). In conjunction with AL, risk 
management systems (RMS) are increasingly being used as a means of overcoming the 
µYDOOH\RIGHDWK¶HFRQRPLFLVVXHVIDFLQJGHYHORSHUVRILQQRYDWLYHELRPHGLFDO
treatments. The UK has been at the forefront of these developments, introducing 
schemes where, for instance, the manufacturer reimburses drug costs if long term 
HQGSRLQWVDUHQRWPHWRUIRUSDWLHQWVZKRGRQ¶WUHVSRQGWRWKHWUHDWPHQWDVZHOODV
cost-limiting schemes such as cost discounts, dose capping and free first cycles to limit 
the initial outlay on experimental treatments whilst still providing some reimbursement 
for manufacturers (OECD, 2013). These examples suggest that although regenerative 
medicine policy rhetoric emphasises both health and wealth, in practice policy 
initiatives often focus particularly on addressing commercial and economic challenges. 
In line with the policy environment, the European regulatory framework for cell therapy 
trials also appears to be underpinned by a commercial innovation model. The Advanced 
Therapy Medicinal Product (ATMP) regulations, which were introduced in 2007, mean 
that the majority (although not all) of the novel cell therapies being developed and 
trialled in the UK are classed as medicinal products (Abou-El-Enein et al., 2013). 7KHUH
DUHWZRNH\IDFWRUVWKDWGHWHUPLQHZKHWKHUDFHOOWKHUDS\LVGHVLJQDWHGDVDQ$703
ZKHWKHUWKHFHOOVKDYHEHHQVXEVWDQWLDOO\PDQLSXODWHGDQGRUDUHQRWEHLQJXVHGLQWKHLU
RULJLQDOIXQFWLRQQRQKRPRORJRXVXVH7KHUHDUHIRXUFDWHJRULHVRI$703WLVVXH
HQJLQHHUHGSURGXFWVJHQHWKHUDS\SURGXFWVVRPDWLFFHOOWKHUDS\SURGXFWVDQG
FRPELQHGSURGXFWV(EMA, 2015)0RVWFHOOWKHUDSLHVFODVVLILHGDV$703VIDOOZLWKLQ
WKHVRPDWLFFHOOWKHUDS\FDWHJRU\VHH)LJXUH  
$VPHGLFLQDOSURGXFWV$703VDUHVXEMHFWWRWKHVDPHUHJXODWRU\IUDPHZRUNDV
SKDUPDFHXWLFDOV7KLVPHDQVDQ$703PXVWKDYHDPDUNHWLQJRUFOLQLFDOWULDO
DXWKRULVDWLRQLQRUGHUWREHXVHGLQWKHFOLQLFDOWKRXJKWKH+RVSLWDO([HPSWLRQVSHFLDOV
URXWHGLVFXVVHGEHORZGRHVDOORZIRUOLPLWHGXVHLQDQLQGLYLGXDOKRVSLWDOVHWWLQJ
&OLQLFDOWULDOVRIPHGLFLQDOSURGXFWV&7,03Vcome under the Medicines for Human 
Use (Clinical trials) Regulations and are therefore much more heavily regulated than 
non-CTIMPs. They PXVWEHDSSURYHGDQGLQVSHFWHGE\WKHQDWLRQDOFRPSHWHQW
DXWKRULW\ZKLFKLQWKH8.LVWKH0HGLFLQHVDQG+HDOWK5HVHDUFK$XWKRULW\0+5$, 
and the Investigational Medicinal Product (IMP) must be produced under Good 
Manufacturing Practice (GMP) conditions. There is an expectation that IMPs will 
follow a phased approach to trials, being tested first in Phase 1 safety and dosing studies 
with volunteers followed by Phase 2 studies in a small number of patients and then 
Phase 3 studies with large samples. This framework mirrors that of pharmaceuticals, 
which are typically developed commercially (see discussion of commercial CTIMPs 
below), and contrasts markedly with many other areas of medicine and public health, 
such as surgery or mental health interventions, where innovation is largely clinically-
driven, clinical trials are not regulated by the MHRA, the phased approach is less 
common and no marketing authorisation is required in order to deliver the intervention 
to patients. 
3.2 Trials activity in the public sector 
In contrast to the commercial model which appears to underpin the regulatory and 
policy framework for cell therapies trials, my research found that in the UK the majority 
(73%) of trials are currently being undertaken in the public sector. This is in line with 
the global picture for cell therapy trials (see for instance Li, Atkins, and Bubela 2014; 
Foley and Whitaker 1012), but it is at odds with the characteristics of clinical trials 
overall (i.e. trials of all types of treatment). For instance, commercial trials outnumber 
publicly-funded trials by a ratio of 2:1 in terms of total UK trial activity (Will 2011), 
whereas this ratio is reversed for cell therapies. The difference is even more marked 
when compared to CTIMPs; for instance, data published by the MHRA indicates that 
commercial trials account for around 95% of Phase 1 CTIMPs and 90% of Phase 2 and 
3 studies (MHRA 2019). This is mainly because early-phase cell therapy trials are 
DOPRVWDOOµLQYHVWLJDWRU-OHG¶PHDQLQJWKH\DUHUXQE\WKHFOLQLFLDn/academic developing 
the treatment rather than by a company. Commercial investment has thus far largely 
focussed on treatments that have already shown some degree of clinical efficacy, as 
highlighted by this quote: 
Cell manufacturer working in a clinical lab: ³7KHVHDUHVWLOOLQYHVWLJDWRUGHYHORSHG
SURGXFWVVRWKH\¶UHQRWFRPLQJIURPSKDUPDFHXWLFDOFRPSDQLHV3KDUPD¶VEX\LQJ
WKHPDIWHUDVHDUO\DV3KDVH3KDVHGDWDEXWWKH\¶UHQRWEHLQJGHYHORSHGE\
WKHP´ 
This divergence from the typical drug development pathway may be partly because 
pharmaceuticals are relatively straightforward molecules and can generally be 
administered to patients in a non-invasive way. In contrast, cell therapies are living 
organisms which present considerable clinical and scientific complexities and 
uncertainties when used as a therapeutic agent, and the majority of interviewees felt that 
because of this complexity the early stages of cell therapy development (including 
early-phase trials) will always be dominated by academia. 
3.3 Policy and regulatory challenges for clinical-academic trials 
The unusual preponderance of cell therapy trials taking place in the public sector creates 
a number of challenges, not least because classification as a medicinal product makes 
trials extremely expensive to run. Public funding is often insufficient to run these type 
of trials successfully, as highlighted by the experience of these interviewees: 
7ULDOPDQDJHU³2QHRIWKHGLIILFXOWLHVZDVZHDSSOLHGIRUIXQGLQJWRDQ
organisation that was knoZQWRVXSSRUWLQQRYDWLYHSURMHFWV«EXWZKRVHJUDQW-
JLYLQJDELOLW\ZDV«SUREDEO\RUPD\EHRIZKDWZHDFWXDOO\QHHGHG
HVSHFLDOO\LQWKHQHZWHUUDLQ´ 
 
&OLQLFDOUHVHDUFKHU³2XUILUVWWULDOFDPHIURP>FKDULW\@DQGLWZDVYHU\
underfunded because again, when I put the grant in there was no regulatory hurdles 
DWDOOVRLWZDVQ¶WIDFWRUHGLQ´ 
It is difficult to generalise about the exact cost of cell therapy trials (or indeed clinical 
trials in general) for a number of reasons. Firstly, the cost of commercial trials is 
commercially sensitive and is therefore rarely available in the public domain. The 
funding awarded for a publicly-funded trials is occasionally made public, for instance 
the NIHR (National Institute of Health Research) publicises amount of grants awarded 
under its clinical research funding streams, but this is far from universal. Furthermore, 
the amount of the award may not be a good representation of the actual cost of running 
the trial, either because the grant funds other research as well as the trial or because it 
does not cover the full costs. Although this makes it difficult to estimate the average 
cost of a cell therapy trial, a number of interviewees described approximate costs for 
different aspects of the trial. For instance, these quotes suggest that in addition to the 
cost of running the trial, the cost of the treatment itself and the ongoing cost of 
maintaining the research team to run the trials can both be significant: 
&OLQLFDOUHVHDUFKHU³<RXQHHGWRSD\WKLVWUHDWPHQWZhich might cost you know 
SHUSDWLHQWIRUD3KDVHVWXG\ZKHUHDWWKHHQGRILWZH¶UHQRWJRLQJWR
NQRZLILWZRUNVRUQRW«LW¶VMXVWQRWWHQDEOH´ 
 
6FLHQWLILFUHVHDUFKHU³:HKDYHDQRXWILWDWWKHPRPHQWWKDWFRVWVD\HDU
run, and we haYHDWWKHPRPHQWRQH\HDU¶VIXQGLQJOHVV- we are funded at the 
PRPHQWXQWLO-DQXDU\QH[W\HDUDWZKLFKSRLQWZHZLOOGLVDSSHDULIZH¶UHQRW
IXQGHGDQ\IXUWKHU´ 
The cost of running large, highly regulated trials of expensive experimental treatments 
led many interviewees to conclude that commercial involvement will be essential for 
the successful development of many cell therapies: 
Clinical/scientific researcher: ³8OWLPDWHO\ZKHQZHPRYHWRVWHPFHOOWKHUDSLHVLW¶V
JRLQJWRJRWRDFRPSDQ\EHFDXVH\RX¶UH QHYHUJRLQJWRVXVWDLQLWDFDGHPLFDOO\´ 
 
Clinician who acted as Chief Investigator for a commercial trial: ³:HZHUHVRUWRI
the pioneers, even though it was a commercial study. And in that sense, it was 
quite a good one to take forward because we had those resources ... if you were 
WU\LQJWRGRWKLVDFDGHPLFDOO\LWZRXOGEHUHDOO\H[SHQVLYH´ 
The implication of the need for commercial funding for trials is that most interviewees 
felt that commercial considerations will inevitably have a significant influence on the 
development of these treatments, as demonstrated in these quotes: 
Clinical researcher: ³,WGRHVQ¶t matter if you can cure all of your patients, unless 
VRPHRQHFDQPDNHPRQH\RXWRILWLW¶VQRWJRLQJWRJRDQ\ZKHUH´ 
 
Scientific researcher: ³,W¶V[the CGTC] clearly set up by a Tory government 
EHFDXVHWKHLUSULPDU\DLPLVDFWXDOO\WRJHQHUDWHZHDOWKEXW,GRQ¶WVHHZK\WKDW¶V
VXFKDEDGWKLQJ´ 
The first of these quotes suggests a grudging acceptance of the economic realities of cell 
therapy development, but the second suggests a slightly more enthusiastic endorsement 
RIWKHµZHDOWK¶REMHFWLYHVXQGHUSLQQLQJFXUUHQWLQQRYDWLRQSROLF\6RPHLQWHUYLHZHHV
felt that there were in fact significant benefits to commercial involvement in the field, 
such as academic reVHDUFKHUVEHLQJDEOHWROHDUQIURPSKDUPDFHXWLFDOFRPSDQLHV¶
expertise in trial design or knowledge of the regulatory framework. Commercialisation 
thus appears to be tolerated, and in some cases even welcomed, in order to facilitate the 
development of expensive treatments that are likely to benefit patients. 
Despite recognising the economic necessity of commercialising cell therapies, many 
interviewees felt that aspects of the commercial model were not appropriate for their 
treatments. For instance, many cell therapies do not fit well with the pathway of 
undertaking large Phase 3 trials before applying for marketing authorisation, as 
explained in this quote: 
Cell manufacturer working in a clinical lab: ³+RZZRXOG\RXPDNHLWIRU
patients? You couldn¶W,GRQ¶WEHOLHYHLQWKHFXUUHQWZD\WKDWRQHDVVHVVHVDGUXJ
for a marketing authorisation, that something like a tissue engineered trachea or 
ODU\Q[RURHVRSKDJXVFRXOGJHWDPDUNHWLQJDXWKRULVDWLRQ´ 
This interviewee went on to explain that he thought it would be difficult to enforce 
marketing authorisations for cell therapies with complex production processes, where it 
would essentially be the process rather than the end product that would be the subject of 
the authorisation: 
³:H¶YHMXVWVHHQWKDWDn Italian company has got a marketing authorisation for 
OLPEDOVWHPFHOOWUDQVSODQWV,GRQ¶WNQRZKRZZHOOWKDW¶VJRLQJWRVWDQGXSRU
LQGHHGLILW¶VGHIHQVLEOH7RGRDOLPEDOVWHPFHOOWUDQVSODQW\RXKDYHWRWDNHOLPEDO
cells from the good eye, grow them on a substrate and then implant that substrate 
on the bad eye. So in terms of a licensed medicine, if someone just uses a different 
VXEVWUDWHLW¶VDGLIIHUHQWPHGLFLQH´ 
These quotes suggest that the trials framework for cell therapies, which mirrors that of 
pharmaceuticals, may be misaligned with a clinical reality which has more in common 
with surgical techniques and other complex interventions, which typically follow a 
different trialling process. 
The commercial model underpinning cell therapy policy and trial regulation also 
appears to limit the effectiveness of many of the initiatives introduced to alleviate the 
challenges of conducting clinical trials. For instance, there was a notable contrast in 
attitudes towards the CGTC between commercial interviewees, who tended to be very 
engaged with it and positive about its impact, and clinical-academic interviewees, who 
appeared to find it less relevant to their concerns. For instance, one interviewee 
suggested that the centralised manufacturing model promoted by the CGTC in order to 
support trials was not relevant to his tailored treatment that was better suited to local 
manufacturing (i.e. cell manufactured on site at the hospital rather than in a central 
facility): 
Scientific researcher: ³)RUWKHVRUWRI VWXIIZH¶UHGRLQJLQ>GLVHDVHDUHD@ZKHUHLW¶V
QRWMXVWDFHOOEXWLW¶VJRWWRJURZDQGLQWHJUDWHDQGFRQQHFWLW¶VDZKROHSDFNDJH
VR\RXFDQ¶WUHDOO\WDNHLWRIIWKHVKHOI´ 
This quote depicts the manufacturing model for many clinical-academic cell therapies, 
ZKLFKLQYROYHDRQHRIIPDQXIDFWXULQJSURFHVVRIWHQXVLQJDSDWLHQW¶VRZQFHOOV,Q
contrast, centralised manufacturing facilities such as that being developed by the CGTC 
tend to use existing cell lines which can be used to treat many patients ³RII-the-VKHOI´
and are thus unlikely to be viable for such one-off, tailored treatments.   
Other interviewees raised additional FRQFHUQVDERXWWKHUHOHYDQFHRIWKH&DWDSXOW¶V
activities to their trials, in particular suggesting a lack of focus on the institutional 
challenges perceived to be one of the biggest barriers to cell therapy innovation: 
Clinical researcher: ³,¶GEHLQWHUHVWHGWRNQRZZKDWWKHVWHPFHOOFDWDSXOW>VLF@LV
doing in this area - ,VXVSHFWLW¶VQRWORRNLQJDWWKH1+6LQIUDVWUXFWXUHLVVXHV´ 
 
Clinical cell manufacturer: ³,GRQ¶WWKLQNP\GHSDUWPHQW- any hospital department 
- FRXOGUHDFKDQ\OHYHOWKDWZH¶OOEHDEOHWRVHOODPHGLFLQH6RWKDW¶VZKDW&DWDSXOW
ZDQWLVQ¶WLWWKH\¶UHQRWERWKHUHGDERXWWKH1+6´ 
Ultimately, most clinical-academic interviewees felt that the CGTC, one of the most 
important policy initiatives for regenerative medicine, was unlikely to be of much value 
to them. Indeed, a number expressed concern that the increased prominence of the 
centralised model could lead to funds and expertise being diverted away from therapies 
that require local manufacturing, threatening the long-term future of these treatments.  
Just as the CGTC tended to be seen as at best irrelevant by clinical-academic 
interviewees, so too were the initiatives being pursued to address commissioning and 
reimbursement challenges for cell therapy trials. There was very little awareness of 
either adaptive licensing or risk management systems, even when prompted, and 
notably the only interviewee who made any spontaneous reference to either was a 
commercial cell therapy developer. The lack of interest in these initiatives is probably 
partly because they are aligned with the marketing authorisation model that, as already 
noted, is not felt to be practical or appropriate for many cell therapies being developed 
under the clinical-academic model. Perhaps most importantly, however, neither of them 
addresses another reimbursement issue that my research identified as being by far the 
most important for clinical-academic trials, which is excess treatment costs. Unlike 
commercial trials, where the company pays for the therapy, treatment costs for publicly-
funded trials are met by the NHS. For cell therapy trials these costs can be extremely 
high, and many interviewees described securing reimbursement as time consuming, 
uncertain and in some cases entirely impossible. For instance, the ENABLE team had to 
spend a considerable amount of time securing funding for each trial participant 
individually, despite the NICE guidelines stating that the treatment should be 
reimbursed if it was delivered as part of a clinical study. In some cases the funding was 
denied and the patient could not be recruited, delaying the progress of the trial, and 
some of these patients had to be withdrawn after randomisation meaning they could not 
be replaced and weakening the scientific validity of the results. This sort of challenge 
appears to be common and led many interviewees to voice concerns about the 
sustainability of clinical-academic trials. Excess treatment costs are clearly then a 
significant issue for cell therapy innovation and are entirely unaddressed by current 
policy initiatives, which predominantly address the reimbursement challenges of 
commercially-developed cell therapies. 
3.4 The role of institutions in imagining the future of cell therapies 
Overall, this analysis suggests that the emerging institutions of cell therapy trials, both 
those specific to cell therapies (such as the CGTC) and those that order knowledge 
production and innovation in medicine more generally (such as the EMA and the 
MHRA) tend towards a commercial model of innovation. This aligns with other 
research that suggests the current regulatory and policy framework tends to marginalise 
non-commercial innovation. For instance, Sanchez et al. (2013) found that the 
commercial route can be limiting for academic-initiated trials in the US, and Cuende et 
al. (2014) argue that the ATMP legislation is not suited to treatments that do not have a 
commercial interest.  The institutions of cell therapy trials are thus implicitly endorsing 
a desirable future for cell therapies which prioritises the commercial model, and the 
combined influence and reach of these institutions imbues this vision with considerable 
power. A good example of the role played by institutions in establishing dominance for 
a particular socio-WHFKQLFDOLPDJLQDU\LV0LOOHU¶VGHVFULSWLRQRIWKH
Intergovernmental Panel on Climate Change (IPCC), which was instrumental in 
repositioning climate change from a localised weather phenomenon to a globalised 
concern. There are echoes of this in the actions of the CGTC, which in positioning cell 
therapy production as a centralised commercial activity has potentially marginalised 
those treatments and sites currently using a localised clinical-academic manufacturing 
PRGHO7KHGLIIHUHQFHEHWZHHQWKLVDQG0LOOHU¶VGHVFULSWLRQRIWKH,3&&KRZHYHULV
the fact that the institutional positioning of cell therapies involves the interaction of a 
number of different institutions, such as the EMA, MHRA and CGTC. The social order 
of cell therapies, then, can be understood as emerging from the assumptions and 
authorities invoked by these institutions, which interlock and mutually reinforce to 
produce a specific conceptualisation of the future of cell therapies.  
4. Identity making in cell therapy trials 
4.1 Clinical-academic identity ± emphasising knowledge and care over profit 
The commercial model underpinning the cell therapy trials regulatory 
framework is distinctive largely because, unlike pharmaceutical regulation, it is being 
applied to innovation taking place largely in clinical-academic settings. Some 
interviewees suggested that academia may be particularly suitable for the early stages of 
cell therapy development because the combination of clinical complexity and scientific 
uncertainty make the early stages of innovation inherently unpredictable, as explained 
in this quote: 
Scientific researcher: ³0RVWDGYDQFHVUHTXLUHDQLQGLYLGXDOZKRDEVROXWHO\
dedicates him or herself to it and will take the time to do it properly. However 
PXFK\RXFDQVD\³\HVZH¶UHRQWKHYHUJHRIDKLVWRULFDGYDQFHLWQHHGVDEFDQG
GOHWXVHPSOR\SHRSOHWRGRDEFDQGGDQGLWZLOOJHWGRQH´- LWZRQ¶W,W¶VWRR
FRPSOLFDWHGDQGWKHUH¶VWRRPXFKDSSOLFDWLRQWRGHWDLOWKHUH¶VWRRPXFKIUXVWUDWLRQ
WREHHQGXUHG´ 
The implication here is the culture and expectations of academic inquiry may be more 
suited to this prolonged, uncertain process than a commercial model, which must 
generate results, and thus profit, relatively quickly. In fact, despite recognising the need 
for commercial input to cover the costs of expensive clinical trials, many clinical-
academic interviewees expressed some discomfort with cell therapies being developed 
as profit-making products at all. Rather, they emphasised the health objectives of cell 
therapy innovation, as exemplified in this comment from an interviewee whose 
scientific research had recently begun to show promising clinical results: 
Clinical/scientific researcher: ³)RULWWREHFRPPHUFLDO\RXKDYHWRKDYHVRPHWKLQJ
patentable that you can sell ... I would be very happy if no patient ever had to pay a 
SHQQ\IRUZKDW,KDGGRQH´ 
In another similar example one interviewee expressed anger about a treatment that had 
initially been developed at his hospital before being bought by a company and pushed 
LQWR³LOO-FRQFHLYHG´WULDOVSUHPDWXUHO\WRH[SHGLWHWKHPDUNHWLQJDXWKRULVDWLRQ
application. When these trials failed to show efficacy the company abandoned 
development and patients already receiving the treatment had it withdrawn, despite they 
and their doctors thinking it was benefiting them. These examples show clinical-
academics emphasising that their priority is to treat patients, differentiating themselves 
from companies which prioritise profit over care, and clearly identifying themselves as 
µFDUH-JLYHUV¶DVRSSRVHGWRµSURILW-PDNHUV¶  
Clinical-academic interviewees also differentiated their identity from the commercial 
model by emphasising their divergent cultural norms and approaches to knowledge 
generation. For instance, one interviewee highlighted the conflict between his 
expectations of transparency and pressure from commercial funders to protect 
commercially-sensitive information: 
Scientific researcher: ³<RX¶YHJRWWKHGUHDGHGFRQILGHQWLDOLW\DJUHHPHQWV«
companies always have their long spiel of conditions, and the one I always cross 
out is that any result of work that goes on in my lab or that I have contributed to 
remains confidential and can only be pXEOLVKHGZLWKFRPSDQ\DSSURYDO,¶PKDSS\
WRJLYHVL[ZHHNV¶QRWLFHEHIRUHDQ\WKLQJLVVXEPLWWHGEXWWKHGDWDLVWKHGDWDDQG
LW¶VQRWJRLQJWREHNHSWVHFUHW´ 
There were also other aspects of the commercial model that academic researchers 
described being uncomfortable with, such as an oncologist who felt that the influx of 
commercial interest following positive signs of efficacy in CAR T-Cells had made 
further research in the field more challenging:   
Clinical researcher: ³7KDWEULQJVWKHEDGVLGHRXW- you start seeing people getting 
protective about reagents, commercial agreements come into place, restricting 
access to other people, meaning that you have to duck and dive with your process 
DQGILQGDOWHUQDWLYHVXSSOLHUV´ 
7KHXVHRIWKHWHUPµEDGVLGH¶LQWKLVTXRWHKLJKOLJKWVWKHUHVHUYDWLRQPDQ\FOLQLFDO-
academic interviewees expressed about commercial activities, even in some cases 
voicing outright suspicion as exemplified here:  
Clinical researcher: ³6RPHRIWKHSKDUPDFHXWLFDOFRPSDQLHVVHWXSWULDls to stymie 
WKHLUULYDOV«WKH\GRDWULDOWKH\GRQ¶WUHDOO\KDYHDQ\JUHDWLQWHUHVWLQEXWLW
PHDQVWKHUHDUHIHZHUSDWLHQWVIRUWKHLUULYDOZLWKDIXQGDPHQWDOO\QHZWUHDWPHQW´ 
The prevalence of these views amongst clinical-academic interviewees suggests their 
involvement with commerce represents at best an uneasy truce between what they 
perceive as two fundamentally different perspectives on how research should be 
undertaken and communicated, as well as what the priorities of that research should be. 
4.2 Trials as a challenge to the clinical-academic identity 
Identification as a care-giver was used by some clinical-academics to question 
the relevance of restrictive clinical trial requirements designed for products being 
GHYHORSHGE\µSURILW-PDNLQJ¶FRPpanies, as expressed by this interviewee when 
GHVFULELQJKLVUHVSRQVHWREHLQJFKDOOHQJHGDERXWµFKHUU\SLFNLQJ¶GDWDIURPDWULDO
rather than only reporting pre-specified outcome measures:  
Clinical/scientific researcher: ³3HRSOHKDYHWKLVKXJHVXVSLFLRQof all of this, and 
\RXVD\ZHOOWKHUH¶VQRWKLQJZURQJZLWKLW- ,¶PQRWWU\LQJWRVHOODSURGXFW´ 
Clinical-academic researchers also tend to lack experience of Clinical Trials of 
Investigational Medicinal Products (CTIMPs), in fact despite all being responsible for at 
least one cell therapy trial none of the clinical-academic researchers I interviewed were 
trial specialists, and only one had any prior experience of trialling at all. The 
investigators setting up and running cell therapy trials are thus unfamiliar with 
regulatory requirements and lack expertise in trial design, meaning they are less likely 
to use complex or innovative methods that could make trials more efficient. Many 
interviewees felt that their inexperience had hampered the process or resulted in aspects 
of the trial being more difficult than necessary, as exemplified by this quote:  
Clinical researcher: ³,WKLQNEHFDXVHLWZDVVXFKDELJVWHSDQGVRXQIDPLOLDUWR
me, I did what a lot of people do in those circumstances and just sort of made it a 
ELWWRRFRPSOLFDWHG´ 
This inexperience is compounded by the fact that the regulatory demands of running a 
CTIMP do not align well with the priorities and practices of academic research. For 
instance, one interviewee highlighted how the issues that trials need to address do not 
tend to be those that academics want to focus on: 
Clinical/scientific researcher: ³$ORWRIWKHTXHVWLRQVDUHYHU\ERULQJDQGWKH\¶UH
not scientifically very interesting. But ultimately they will determine whether your 
theUDS\ZRUNV´ 
In another example a clinician voiced his concern that the scientific researcher involved 
in his trial might find her career adversely affected by her involvement because trials 
DUHOHVVOLNHO\WKDQEDVLFVFLHQWLILFUHVHDUFKWRJHQHUDWHWKHµVLJQLILFDQW¶ILQGLQJVQHHGHG
to publish in high impact journals. It seems, then, that despite clinical-academic 
investigators being integral to the trialling process for cell therapies, this process is both 
unfamiliar to them and can conflict with their own priorities and motivations for 
undertaking research. 
Concerns about the relative distribution of risks and benefits appears to be another area 
of tension between the clinical-academic identity and the commercial model of 
innovation in trials. In particular interviewees were concerned that the financial burden 
(and risk) of undertaking pre-clinical development and early-phase trials is largely being 
borne by the public sector. The current model of early trials being largely investigator-
led provides a cost-efficient way for companies to identify treatments which have real 
clinical potential, as exemplified in this quote: 
Cell manufacturer working in a clinical lab: ³3KDUPDVHHLWDVDQHZSDUDGLJPWKDW
saves them money - it de-risks the process if someone in academia is doing an 
early phase trial and shows efficacy. One in a thousand drugs gets through to Phase 
EXWVRPHRQHKDVGRQH\RXU3KDVHDQG\RX¶UHEX\LQJLWZKHQ\RX¶YHJRWVDIHW\
GDWDDQG\RX¶YHJRWVRPHHIILFDF\´ 
7KHXVHRIWKHSKUDVHµGH-ULVN¶ is important here, because of course the risks of 
undertaking early trials have not been eliminated in this model, they have simply been 
transferred from the commercial to the public sector. The public sector does not 
necessarily have a corresponding share of the potential benefits of innovation, however, 
because once bought by a company a cell therapy becomes a product that must be paid 
for - and the costs are likely to be high. For many interviewees this was a significant 
concern for the future, articulated here by a researcher involved in the development of 
an expensive cell therapy: 
Clinical/scientific researcher: ³0\JUHDWHVWDQ[LHW\LVZHGHYHORSDVWHPFHOO
WKHUDS\WKDWZRUNVLQFUHGLEO\ZHOOZHWKLQNZH¶YHJRWDZRQGHUIXOWUHDWPHQWWR
offer people wLWK>GLVHDVH@DQGWKHQVXGGHQO\\RXGLVFRYHUZHFDQ¶WDIIRUGLW´ 
This quote encapsulates the fundamental difficulty at the heart of cell therapy 
innovation: the clinical-academic and commercial models can support each other in 
order to both improve health and generate wealth, but they also have different priorities 
which can compete with and potentially impede each other.  
4.3 Hospital exemption: an alternative model for clinical academic innovation? 
 7KHFKDOOHQJHVFDXVHGE\$703FODVVLILFDWLRQFDQEHDYRLGHGLQFHUWDLQ
FLUFXPVWDQFHVEHFDXVHDOWKRXJK$703VJHQHUDOO\UHTXLUHHLWKHUDPDUNHWLQJRUFOLQLFDO
WULDODXWKRULVDWLRQWKHOHJLVODWLRQDOORZVIRUWKHH[HPSWLRQRIWUHDWPHQWVWKDWDUH
³SUHSDUHGRQDQRQ-routine basis according to specific quality standards, and used 
within the same Member State in a hospital under the exclusive professional 
responsibility of a medical practitioner, in order to comply with an individual medical 
prescription for a custom-PDGHSURGXFWIRUDQLQGLYLGXDOSDWLHQW´(Cuende et al., 2014)
,QHYLWDEO\WKLVH[HPSWLRQKDVEHHQLQWHUSUHWHGGLIIHUHQWO\E\WKHYDULRXVPHPEHUVWDWHV
ZLWKWKHWHUPV¶FXVWRPPDGH¶µLQGXVWULDOSURFHVV¶DQGµQRQURXWLQH¶DOOEHLQJRSHQWR
LQWHUSUHWDWLRQ,QWKH8.WKHUDSLHVPXVWEHSUHSDUHGZLWKLQWKHVDPHKRVSLWDOWREH
HOLJLEOHXQGHUZKDWLVNQRZQDVWKH+RVSLWDO([HPSWLRQ+(DQGWKHVHSURGXFWVGRQRW
UHTXLUHD43WRVLJQWKHPRII(Cuende et al., 2014)$OWKRXJKSURYLGLQJWKHOHDVW
UHVWULFWLYHRIWKHUHJXODWRU\RSWLRQVIRUSURGXFLQJFHOOWKHUDSLHVDWWKHWLPHRIZULWLQJ
WKHUHZDVRQO\RQHVLWHLQWKH8.NQRZQWREHSURGXFLQJFHOOVXQGHU+(,WGRHVQRW
WKHUHIRUHDSSHDUWREHDVLJQLILFDQWURXWHIRUWKHGHYHORSPHQWRIVXFKWUHDWPHQWVD
FRQFOXVLRQVXSSRUWHGE\WKHIDFWWKDWPDQ\LQWHUYLHZHHVKDGQRWKHDUGRILW 
7KHUHODWLYHobscurityRI+(LQWKH8.PD\EHSDUWO\GXHWRWKHH[LVWHQFHRIDQ
DOWHUQDWLYHWKHVRFDOOHGµVSHFLDOV¶URXWHZKLFKSURYLGHVDVLPLODUIUDPHZRUNIRUWKH
GHOLYHU\RIPHGLFLQDOSURGXFWVZLWKRXWDPDUNHWLQJDXWKRULVDWLRQ0+5$7KLV
LVPRUHUHVWULFWLYHWKDQ+(LQVRPHZD\VIRULQVWDQFHWKHUHTXLUHPHQWIRUD43WRVLJQ
RIIEDWFKHVRISURGXFW+RZHYHUDVSHFLDOVOLFHQFHSURYLGHVJUHDWHUVFRSHIRUWKH
GHOLYHU\RIFHOOWKHUDSLHVEHFDXVHWKHXVHRIWKHSURGXFWLVQRWUHVWULFWHGWRWKHKRVSLWDO
ZKHUHLWZDVSUHSDUHGDQGLQGHHGLWPDNHVLWSRVVLEOHWRLPSRUWDQGH[SRUWXQOLFHQVHG
PHGLFLQDOSURGXFWV(Cuende et al., 2014)7KHUHLVQRFHQWUDOLVHGGDWDDYDLODEOHRQWKH
QXPEHURUW\SHRIFHOOWKHUDSLHVEHLQJGHOLYHUHGXQGHUVSHFLDOVOLFHQFHVRUKRZPDQ\
SDWLHQWVKDYHEHHQWUHDWHG+RZHYHUWKHUHDUHDWRWDORIVLWHVZLWKOLFHQFHVWR
PDQXIDFWXUHFHOOWKHUDSLHVIRUKXPDQXVH(MHRA, 2015)DQGDQXPEHURILQWHUYLHZHHV
GHVFULEHGVXFKFHOOVEHLQJLQUHJXODUXVH 
,WDSSHDUVWKHQthatDOWKRXJKLWLVQRWSRVVLEOHWRTXDQWLI\H[DFWO\KRZPDQ\FHOO
WKHUDSLHVDUHGHOLYHUHGWRSDWLHQWVXVLQJKRVSLWDOH[HPSWLRQRUVSHFLDOVOLFHQFHV
UHIHUUHGWRKHUHDIWHUDV+(IRUEUHYLW\LWLVFHUWDLQO\DVLJQLILFDQWURXWHIRUWKH
GHOLYHU\RIFHOOWKHUDSLHVLQWKH8.,WGRHVQRWKRZHYHUDSSHDUWRRIIHUFOLQLFDO
DFDGHPLFLQQRYDWLRQDYLDEOHDOWHUQDWLYHWRFOLQLFDOWULDOVDQGPDUNHWLQJDXWKRULVDWLRQ
0RVWLQWHUYLHZHHVIHOWWKDW+(ZDVRQO\DSSURSULDWHIRUWUHDWPHQWVWKDWDOUHDG\KDYH
HYLGHQFHRIHIILFDF\RUDVDSUHFXUVRUWRDWULDOUDWKHUWKDQDVDQDOWHUQDWLYHURXWH )RU
LQVWDQFHWKLVLQWHUYLHZHHH[SODLQHGWKDWKHKDGPRYHGVWUDLJKWWRDFOLQLFDOWULDOUDWKHU
WKDQFRQVLGHULQJ+(EHFDXVHKHIHOWWKDWWKHFROOHFWLRQRIHYLGHQFHIURPµSURSHU¶WULDOV
ZDVLPSRUWDQWIRUWKHVFLHQWLILFGHYHORSPHQWRIWKHILHOG 
&OLQLFDOUHVHDUFKHU³,W¶VQRWJRRGVFLHQFHUHDOO\EHFDXVHZKDWZHUHDOO\QHHG
especially in cell therapy, are properly designed clinical trials to be executed 
and completed. And we still see even now in my field some really uber-
eminent people publishing case reports and series, and two or three patients 
in the New England Journal of Medicine. And they are remarkable results, but 
WKDW¶VQRWDSURSHUFOLQLFDOWULDO´ 
 
7KLVTXRWHVXJJHVWVVFHSWLFLVPDERXWWKHHYLGHQFHJHQHUDWHGE\LQGLYLGXDOFOLQLFDOFDVHV
FRQGXFWHG+(ZKLFKLVUHIOHFWHGLQDQRWKHUFRQFHUQUDLVHGDERXWZKHWKHUHYLGHQFH
JHQHUDWHGWKURXJK+(ZRXOGEHDFFHSWHGE\TXDOLW\MRXUQDOVRUFRXOGEHXVHGWRVXSSRUW
IXUWKHUFOLQLFDOGHYHORSPHQW 
&OLQLFDOUHVHDUFKHU³:HWKRXJKWDERXWVSHFLDOVOLFHQFHVDQGDOOVRUWVRIRWKHU
ways round it, but at the end of the day we knew we wanted to publish our 
GDWD$QGLIZHGLGQ¶WJRWKURXJKWKHUHJXODWRU\URXWHZHZRXOGQ¶WEHDEOHWR
publish it, or we certaiQO\ZRXOGQ¶WEHDEOHWRXVHWKRVHGDWDLQWHUPVRIWKH
QH[WSKDVHRIRXUZRUN«,WKLQNWKHUHZDVVRPHQDJJLQJGRXEWWKDWKDGZH
not gone through the regulatory process would it disqualify our publication 
IURPWKDWMRXUQDO´ 
 
7KHIDFWWKDWVRPDQ\LQWHUYLHZHHVZHUHLQIDYRXURIVWUXFWXUHGWULDOVWKXVDSSHDUVWREH
PRWLYDWHGQRWRQO\E\WKHEHOLHIWKDWWULDOVJHQHUDWHPRUHUREXVWHYLGHQFHWKDQFOLQLFDO
H[SHULHQFHDORQHEXWDOVRE\DQDZDUHQHVVWKDWWULDOHYLGHQFHLVPRUHOLNHO\WREH
DOLJQHGZLWKWKHH[SHFWDWLRQVRINH\GHFLVLRQPDNHUVLQWKHIXWXUH 
As well as concerns about the validity and acceptability of the evidence generated 
through HE for experimental treatments, my findings also suggest that it may not 
always be a sustainable alternative to commercialisation for more proven treatments. 
For instance, although the team at the ENABLE trial site were keen to continue 
developing their cell therapy within the hospital, they were not enthusiastic about 
applying for marketing authorisation. There appeared to be a number of reasons for this, 
perhaps most importantly the fact that they felt a marketing authorisation would require 
them to produce the treatment on demand for other sites, which did not fit with their 
production model. There also appeared to be a lack of desire within the hospital trust to 
commercialise the treatment, and the collaborative way that the team were working with 
other sites to further develop the manufacturing process also did not appear to lend itself 
to the marketing authorisation model. However there was uncertainty and anxiety in the 
team about whether this was the best long-term approach, because of concerns that if 
they did not have marketing authorisation for their treatment and another (likely 
commercial) provider ever did get authorisation that they would find themselves unable 
to continue producing it for their patients. 
4.4 The clinical-academic narrative of cell therapy innovation 
7KH(1$%/(WHDP¶VDSSURDFKDSSHDUVWRHQFDSVXODWHWKHFOLQLFDO-academic identity, 
and the desirable future it envisions. This identity emphasises and draws authority from 
the clinical-DFDGHPLFUROHDVµFDUH-JLYHU¶DVRSSRVHGWRµSURILW-PDNHU¶GUDZLQJRXWWKH
tensions that clinical-academic researchers perceive between these two interests. These 
tensions reflect important practical, cultural and moral divergences between the two 
spheres. At a practical level, the clinical-academic identity is characterised by a lack of 
the financial resources, infrastructure and expertise required for undertaking highly-
regulated drug trials, and it tends towards a localised manufacturing model that does not 
lend itself to commercialisation. On the other hand, it is presented as having strengths 
that the commercial model lacks, particularly in the way that individual or small teams 
of clinicians and academics are able to dedicate themselves to an uncertain and 
prolonged innovation process which is ill-suited to the commercial model. Culturally, 
the clinical-academic identity promotes a collaborative and transparent innovation 
processes and is often resistant to or ambivalent about pursuing the commercial aspects 
of cell therapy innovation, such as intellectual property or marketing authorisation.  
From a moral perspective, clinical-academic researchers often express distaste for 
commercial priorities taking precedence over clinical need, and voice suspicion about 
restrictive or even underhand commercial practices. In the context of these tensions it is 
unsurprising that the clinical-academic identity is distinguished by significant 
reservations about the impact of commercialisation on cell therapy innovation, even as 
individual researchers tend to understand and accept its importance from an economic 
perspective. 
5. Discussion 
These findings suggest a disconnect between a commercial model of innovation 
enacted by the institutions of cell therapy trials and a clinical-academic identity that 
underpins the conduct of the trials themselves. The intersection of the academic and 
commercial spheres is of course not in itself unusual, indeed the triple helix innovation 
model adopted by most Western economies actively fosters this approach to innovation 
in general (Etkowitz 2008), and regenerative medicine specifically (Salter 2013). What 
appears to be distinctive for cell therapies, however, is the extent to which the clinical-
academic sphere is undertaking clinical trials of medicinal products that are usually 
conducted primarily by companies. These trials are more challenging for clinical-
academic settings than investigator-led trials in other clinical areas, such as surgery, 
which are generally be non-CTIMPs and thus subject to much less stringent regulation 
and oversight. A regulatory regime that has traditionally been applied to drugs being 
developed and trialled by pharmaceutical companies is thus now being applied in 
clinical-academic settings, creating a distinctive configuration of clinical-academic and 
commercial interests in the field of regenerative medicine.  
To some extent the commercial and clinical-academic models appear to have 
complementary strengths that mitigate the limitations of the other. For instance, 
academic research is particularly suited to the uncertain early phases of cell therapy 
development, whereas commercial innovation can provide trials expertise and funding 
that the public sector lacks. These synergies are reflected in the fact that even 
commercial cell therapy trials tend to involve SMEs and/or university spin-outs (such as 
Videregen ReNeuron) rather than multi-national pharmaceutical companies. These 
companies can face similar challenges to the clinical-academic trials, and the 
individuals involved can have strong clinical-academic links. The distinction between 
commerce and care which is emphasised by many clinical-academics may thus in 
actuality be more rhetorical than real.  Nevertheless, commercialisation can be a double-
edged sword for clinical-academic innovation: commercial input is important because 
of the high costs of development, but this means that commercial considerations will 
inevitably shape this development, potentially being prioritised over clinical potential 
and need. 
The differences between the clinical-academic and commercial models can be 
understood in practical terms, such as their relative levels of trials expertise or access to 
funding. However, my findings also suggest that these two models, whilst relying on 
and supporting each other to some extent, also reflect different visions of what the 
future of cell therapies could, or should, look like (see Figure 2 for an overview of the 
key differences between the two). The commercial model envisions a desirable future in 
which cell therapies are developed competitively by companies, distributed universally 
on an open market under marketing authorisation, and above all else generate a profit. 
Conversely, the clinical-academic model envisages a future in which cell therapies are 
developed collaboratively in a clinical setting, distributed at a local level through 
hospitals, and above all else benefit patients. In this way, then, the clinical-academic 
and commercial models can be understood as articulating two different socio-technical 
LPDJLQDULHVIRUFHOOWKHUDSLHVLQWKDWWKH\³HQFRGHQRWRQO\YLVLRQVRIZKDWLVDWWDLQDEOH
though science and technology but also of how life ought, or ought not, to be liYHG´
(Jasanoff 2015). Supported as it appears to be by regulation and policy, the commercial 
model could perhaps be understood as the dominant imaginary, with the clinical-
academic model representing an alternative, heterodox vision. It appears to exist in the 
liminal spaces of the dominant commercial model; lacking a cohesive institutional 
framework it struggles to gain or retain traction, despite setting the agenda for the 
scientific and clinical aspects of cell therapy innovation. 
The synergies and tensions between academic research and commercial interests in 
medical innovation are well-documented in the social science literature, and a number 
of studies have described the various configurations and reconfigurations of commercial 
and public interests in clinical research (see for instance Addison 2017; Kohli-Laven et 
al. 2011). In this context, my findings suggest that cell therapy trials create another such 
distinctive configuration of the public and private sector. By undertaking early-phase 
CTIMPS that are more usually run commercially, clinical-academic research is not just 
engaging with commerce it is actually operating in the commercial sphere in ways that 
are new and unfamiliar to many of the individuals involved. The acceptance of the 
commercial socio-technical imaginary by clinical-academic researchers is clearly an 
uneasy one, however, and this is exacerbated by the perception that the public sector is 
shouldering the majority of the cost of early stage clinical trials in cell therapies, whilst 
the commercial sector stands to reap the most benefit. Will (2010) argues that the 
Clinical Research Network model has essentially led to the NHS acting as a Contract 
Research Organisation for commercial research, and my findings suggest that for cell 
therapies this model is heightened and extended. The public sector is not only providing 
the research infrastructure for early-phase trials, it is also designing, managing and 
financing these trials. What this means, of course, is that much of the risk is transferred 
to the public sector, which is undertaking expensive trials but will not benefit 
economically if these trials are successful. The unspoken assumption behind this is that 
these trials will ultimately benefit patients, making this an appropriate use of public 
funds. But if these treatments become either unavailable (because companies choose to 
withdraw them), or unaffordable, this implied contract breaks down. This highlights the 
extent to which commercial and clinical-academic imaginaries, whilst in many ways 
synergistic and inter-dependent, also represent different, and potentially conflicting, 
priorities.  
One of the most useful aspects of using socio-technical imaginaries as an analytical tool 
LVWKDWLWKLJKOLJKWVWKHZD\WKDW³VSDFHDQGVRFLDORUGHUDUHFR-produced in part through 
the spread of ideas and practices - and indeed ideologies - DFURVVWLPHDQGWHUULWRULHV´
(Jasanoff 2015, 22). In the case of cell therapies, the commercial imaginary enacted 
WKURXJKWKHFOLQLFDOWULDOVIUDPHZRUNDSSHDUVWRVHYHUHO\FRQVWUDLQWKHµVSDFH¶DYDLODEOH
for the alternative, clinical-academic imaginary to spread. The demands of the 
commercially-aligned clinical trials framework place a considerable burden on clinical-
academic investigators, and although the hospital exemption does provide an alternative 
IUDPHZRUNIRUGHYHORSLQJFHOOWKHUDSLHVWKH(1$%/(WHDP¶VFRQFHUQVKLJKOLJKWWKH
uncertainty and insecurity of this approach. In the current regulatory framework 
PDUNHWLQJDXWKRULVDWLRQHIIHFWLYHO\µWUXPSV¶HE, which essentially means that clinical-
academic innovation is always at risk of being extinguished by commercial providers. 
The absence of a secure, structured alternative to the CTIMP-marketing authorisation 
pathway thus limits how far clinical-academic cell therapy innovation can progress. 
This is not to say, however, that the heterodox imaginary is destined to be eradicated: 
whilst the commercial imaginary has a powerful institutional framework, the clinical-
academic imaginary is embedded in the identities and day-to-day practices of the people 
undertaking trials. Both imaginaries thus have a strong cultural foundation, and whilst 
the tensions between them are clearly a significant cause of the challenges experienced 
by cell therapy trialists, they also appear to have symbiotic strengths and weaknesses 
which may make them indispensable to each other.  
6. Conclusion 
The dynamic between the two imaginaries described in this paper appears to 
have both productive and conflicting aspects. Commercial and clinical-academic 
involvement are both important elements of the innovation process, with a commercial 
model being necessary because of the high costs of developing and producing these 
treatments, and clinical-academic input being vital because of their scientific and 
clinical complexity and the uncertainties involved in their development. These two 
models do not just represent complementary aspects of innovation, however, they also 
represent different visions of the desirable future for cell therapies. The fact that the 
commercial desirable future is firmly embedded within current regulation and policy 
means that the clinical-academic imaginary is currently somewhat marginalised, despite 
being the driver for the majority of current trialling activity. By implicitly prioritising 
the commercial imaginary, the trials framework is thus promoting certain normative 
assumptions about what we as a society think the future of these treatments should look 
like. It also makes this imagined future more likely to come about, by favouring 
innovation in products that are most likely to have commercial benefit rather than those 
with the most clinical promise, and by increasing the challenges faced by clinical-
academic innovation. Thus, although there are clearly areas where the two socio-
technical imaginaries for cell therapies converge, or complement each other, there are 
also significant tensions between them.  
Jasanoff (2005) argues that in modern knowledge societies democratic negotiation takes 
place not only, or even primarily, through the overtly democratic or political processes 
such as elections. Rather, normative debates about how societies should be run and 
epistemological debates around how they understand themselves take place in multiple, 
often hidden places: in the decisions of regulators, in the wording and application of 
laws, in the allocation of funding and in the production and interpretation of evidence, 
to name but a few. In this context, the extent to which the tensions between the clinical-
academic and commercial imaginaries can be reconciled, allowing them to support 
rather than constrain each other, not only has significant practical implications for only 
innovation in the field, but also has important normative implications concerning what 
we as a society think the balance between these two imaginaries should be, and thus 
what the future of these treatments should look like. 
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